![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves Mylan’s Neulasta Biosimilar
FDA Approves Mylan’s Neulasta Biosimilar
![](https://www.fdanews.com/ext/resources/test/Drug-Images/Mylan_Logo.gif?t=1433878515&width=430)
June 5, 2018
The FDA approved Mylan’s Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta for reducing the chance of infection caused by febrile neutropenia in patients with non-bone marrow cancer.
The medication is meant for patients who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.
The agency cautioned that patients should not take Fulphila if they have a history of allergic reactions to human granulocyte colony-stimulating factors like pegfilgrastim or filgrastim products.
Upcoming Events
-
21Oct